MFM Section Event Meet the Industry: Pharma

1. GSK’s
Vaccines Business
An Vermeersch
1
05 February 2015

2. GSK: A science-led global healthcare company
6
£26.5bn
2013 group turnover
Pharmaceuticals VaccinesConsumer Healthcare
Source: GSK 2013 Annual Report – Published Feb 2014 - http://www.gsk.com/en-gb/investors/corporate-reporting/annual-report/ VGBU/VAC/0003/14

3. A global presence
3VGBU/VAC/0003/14

4. Vaccines in Belgium: Rixensart, Wavre, Gembloux
427/02/2015

5. deaths prevented every
year by vaccination
The value of vaccination
5
children saved from
disability every year
the benefit of vaccines to low-
and middle-income countries
over the next 10 years
estimated annual healthcare
savings over the lifetime of the
people born that year in the US
Sources: 1.Ereth, J. Vaccine 2003; 21:4111 2.GAVI Alliance Partners’ Forum, December 2012 reported by JHB School of Public Health. 3.Immunization and Infectious Diseases. Healthypeople.gov. June 2013
3 million
1
750,0001
$150bn2
$43bn3
Only clean drinking water rivals vaccination in its ability to save lives
To the global economyTo global health
VGBU/VAC/0003/14

6. We are proud of the role we have played
6
Improving
affordability
through tiered pricing
30+
licensed vaccines
Rigorous
clinical trials
worldwide
Over 100
partnerships in
R&D alone
40%
of the world’s children
receive our vaccines
16
candidate vaccines in
development
One standard
all over the world
Success
in partnerships &
collaborative ventures
Innovation
GSK 2013 Annual Report , published February 2014. http://www.gsk.com/en-gb/investors/corporate-reporting/annual-report VGBU/VAC/0003/14

7. Big global challenges remain
7
Human
children under 5 die every day from
largely preventable diseases2
22 million
children without access to vaccines1
19,000
Scientific
people, mostly children, died from
malaria in 20123
34 million
630,000
people were living with
HIV in 20114
approximate proportion of the global
disease burden borne by Africa5
25%
Economic
$550 million
average cost of a new vaccine
manufacturing facility6
Sources: 1. WHO . References April 2013. http://www.who.int/campaigns/immunization-week/2013/event/en/., 2. UNICEF. Millennium Development Goals 2015.
http://www.unicef.org/mdg/index_childmortality.htm, 3. WHO December 2013. Available from: http://www.who.int/mediacentre/factsheets/fs094/en/, 4. WHO. Available from: http://www.who.int/gho/hiv/en/ [last
accessed Dec 2013], 5. WHO, 2013 World Health Statistics report. http://www.who.int/gho/publications/world_health_statistics/EN_WHS2013_TOC.pdf, 6. GSK data on file. 2013.
VGBU/VAC/0003/14

8. A series of environmental challenges and opportunities
are transforming the market
• Increasing emerging market demand
• Increasing private market demand due to patient information and
empowerment
Demand dynamics
• Increased payer sophistication (e.g. GAVI, PAHO)
• Public market price pressure (e.g. EU)
• Differential-priced portfolios from Big-5
• Low-cost competitors compete on price
• Potential price advantage through services and solutions
Price levels
• New entrants compete for share: from developed markets &
emerging marketsCompetitive industry
• Near-term emphasis on LCM (e.g., male HPV), rather than new
blockbusters
• Mid-term high expectation from new categories (e.g., nosocomial,
immunotherapeutics)
Technology

9. Our promise to the
person we help protect
with our vaccines
9VGBU/VAC/0003/14

10. Making our vaccines available to as many people as possible
vaccines are delivered every
day to people in 170 countries1
vaccines go to
developing world2
4 out of 52 million
1. http://www.gsk.com/en-gb/about-us/what-we-do/vaccines/ Last accessed 08/09/14.
2. GSK 2013 Annual Report, P6, published February 2014. 10VGBU/VAC/0003/14

11. invested in core vaccine
R&D in 20131
Innovating where it really matters
£496 million
1.. GSK 2013 Annual Report. http://www.gsk.com/en-gb/investors/corporate-reporting/annual-report
2. http://www.gsk.com/en-gb/research/what-we-are-working-on/product-pipeline/ - last access 08/09/14 11
1 out of 3
of our 16 candidate
vaccines target diseases
particularly prevalent in
the developing world2
VGBU/VAC/0003/14

12. Staking our reputation on our quality: One global standard
State-of-the-art
27
clinical development and
manufacturing process
World class
facilities with highly committed
and qualified people
VGBU/VAC/0003/14

13. 1.GSK 2013 Annual Report. http://www.gsk.com/en-gb/investors/corporate-reporting/annual-report
13
Collaborating widely
partnerships in
R&D alone1
100+
30 years
of collaborative research
to develop our candidate
malaria vaccine1
VGBU/VAC/0003/14

14. That’s our promise
to the person we help
protect with our vaccines
helping them to do more,
feel better, live longer
1414VGBU/VAC/0003/14